Search
for
Sort by
Research 181–210 of 1000+
- Beta-trace protein in chronic inflammatory demyelinating polyradiculoneuropathy and Guillain-Barré syndrome – clinical utilization and a new insight into pathophysiological mechanisms
- Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches within Tumor Cells: A Future Perspective of Cancer Management
- The Association between Number of Follicular Stelae and Severity and Treatment Response of Alopecia Areata Cases: A Retrospective Study
- PO-0071 Role Of Growth Hormone Therapy In Clinical, Laboratory, Radiological Improvement Of Children With Vitamin-d Dependent Rickets Type-2
- PSS38 USE OF CALL CENTRE METHODOLOGY TO COLLECT QUALITY OF LIFE (QOL) DATA IN A CLINICAL TRIAL: A CASE STUDY OF PATIENTS WITH DIABETIC MACULAR EDEMA (DME)
- 1640: Polymorphisms in the 5α-Reductase Type 2 Gene and Response to Finasteride Treatment in BPH
- <i>NIPAL4</i> deletion identified in an American Bully with autosomal recessive congenital ichthyosis and response to topical therapy
- 316 Role of platelet and growth factor concentration in platelet rich plasma therapeutic response to alopecia
- Mogamulizumab‐induced alopecia. Multicentric case series: Clinical, trichoscopic and histological characterization
- VITAMIN D DEPENDENT RICKETS TYPE II (VDR-11). RESPONSE TO PROLONGED THERAPY WITH NOCTURNAL CALCIUM INFUSIONS
- Prediction of therapeutic outcomes of female pattern hair loss patients based on clinical features with application of artificial intelligence
- Hormonal Therapies in Cosmetic Dermatology: Mechanisms, Clinical Applications, and Future Perspectives
- [Implication of VEGF, steroid hormones and neuropeptides in hair follicle cell responses].
- Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response
- Prostaglandin F2α stimulates the growth of human intermediate hair follicles in ex vivo organ culture with potential clinical relevance
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review
- The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- 50-Year-Old Female with a Burning Scalp and Hair Loss
- Lack of response of alopecia areata to pimecrolimus cream
- General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade — a single-center retrospective study
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib
- The microbiome in patients with atopic dermatitis
- Stress-induced Interaction of Skin Immune Cells, Hormones, and Neurotransmitters
- Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapy
- Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms
- Primary Generalized Glucocorticoid Resistance and Hypersensitivity